A model framework to communicate the risks associated with aflatoxins.

Risk communication is defined as the interactive exchange of information and opinions concerning risk, risk-related factors and risk perceptions amongst all the stakeholders of food safety throughout the risk analysis process. The interactive exchange of information occurs at three different levels i.e. informed level, dialogue level and engagement level. For an effective food safety risk communication (FSRC), it is important that the information should adhere to the core principles of risk communication which are transparency, openness, responsiveness and timeliness. Communication of a food safety risk within all the components of risk communication strategy constitutes a complex network of information flow that can be better understood with the help of a framework. Therefore, a model framework to communicate the risks associated with aflatoxins (AFs) dietary intake has been developed with the aim of (a) creating general awareness amongst public and (b) involving industry stakeholders in the prevention and control of risk. The framework has been motivated by the learnings and best practices outlined in the identified technical guidance documents for risk communication. Risk assessors, risk managers, industry stakeholders and general public have been identified as the major stakeholders for the present framework. Amongst them, industry stakeholders and general public has been selected as the major target audience for risk managers. Moreover, population residing in low- and middle-income countries (LMIC) has been identified as the main target group to reach.

Understanding Current Methods for Sampling of Aflatoxins in Corn and to Generate a Best Practice Framework.

Aflatoxin contamination in corn is a significant issue, posing substantial health threats to humans and animals. Aflatoxin testing protects consumer health, ensures the safe global trade of corn, and verifies compliance with legislation; however, effective sampling procedures are essential to ensure reliable results. While many sampling procedures exist, there is no evidence to indicate which is the best approach to ensure accurate detection. Using scientific and gray literature sources, this review analyzed sampling procedures to determine an optimum approach to guide the development of standard practices. Results revealed that sampling is the major source of error in the accurate assessment of aflatoxin levels in food and crucial for obtaining reliable results. To guarantee low variability and sample bias-increased sample size and sampling frequency, the use of automatic dynamic sampling techniques, adequate storage, and homogenization of aggregate samples for analysis are advised to ensure a representative sample. However, there is a lack of evidence to support this or indicate the current utilization of the reviewed procedures. Inadequate data prevented the recommendation of sample sizes or frequency for optimum practice, and thus, further research is required. There is an urgent need to make sampling procedures fit-for-purpose to obtain accurate and reliable aflatoxin measurements.

Maintaining certification compliance of equipment used in hazardous (classified) locations.

In order to understand how to maintain certification compliance of equipment used in hazardous (classified) locations, one must first have an understanding of what a hazardous (classified) location is and what the requirements are for the equipment certification. These will be explained in Part I by Cheryl Gagliardi, a senior engineer with FM Approvals. Part II will cover recommendations for end-user actions for maintaining the certification compliance and will be provided by Bob Baker, an industry consultant to Emerson Process Management.

Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation.

Alemtuzumab is a humanised monoclonal antibody against CD52 used as an immunosuppressive agent in allogeneic HSCT. Regimens including alemtuzumab for allogeneic haematopoietic stem cell transplant (HSCT) conditioning have been associated with an increased incidence of viral complications. Patients with prior toxoplasma exposure undergoing alemtuzumab containing HSCT could therefore be expected to be at a higher risk of toxoplasma reactivation. We conducted a retrospective review of 220 alemtuzumab based allogeneic HSCT performed over a 4 year period, of which 202 were reduced intensity conditioning (RIC) HSCT. A total of 67 patients (30%) in whom the pre-transplant recipient toxoplasma IgG test was positive were classified as high-risk for toxoplasma infection. All patients started trimethoprim/sulfamethoxazole prophylaxis following HSCT when the neutrophil count was > or = 1x10(9)/l. Two high-risk patients developed toxoplasma invasive disease with cerebral involvement at 2 and 4 months post-transplantation respectively. The incidence of toxoplasma disease in the entire cohort and amongst high-risk patients was 0.9% and 3.0% respectively. Despite in vivo T-cell depletion with alemtuzumab, the incidence of toxoplasma disease in our cohort was comparable with previously reported T-cell replete HSCT studies.